Physician profile
Andrew Blank
NPI 1346233475
$5,456.37
in general payments reported to CMS, 2019-2025
31 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2021: $511 · 2022: $1,563 · 2023: $1,923 · 2024: $761 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,937 · Education: $24.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.61 |
| Education | $24.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,229.51 | 2021-2025 | Rinvoq, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $705.79 | 2019-2024 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $509.07 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Madrigal Pharmaceuticals | $299.35 | 2024-2025 | Rezdiffra |
| Janssen Biotech, INC. | $276.14 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $269.96 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $258.31 | 2019-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $246.39 | 2021 | |
| Ironwood Pharmaceuticals, INC | $202.42 | 2022-2024 | Linzess |
| Allergan, INC. | $150.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $137.59 | 2022-2024 | Ocaliva |
| Ardelyx, INC. | $133.47 | 2022-2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $130.04 | 2022-2023 | Entyvio |
| Ferring Pharmaceuticals INC. | $126.86 | 2022-2023 | Rebyota |
| Celgene Corporation | $105.91 | 2022-2023 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $95.92 | 2022-2024 | |
| Daiichi Sankyo INC. | $92.29 | 2022-2024 | Injectafer |
| Braintree Laboratories, INC. | $91.73 | 2022-2023 | Sutab |
| Lilly USA, LLC | $59.98 | 2024 | Omvoh |
| Medtronic, INC. | $56.61 | 2025 | Stealthstation S8 Platform |
| Ars Pharmaceuticals Operations, INC. | $49.60 | 2025 | Neffy |
| Evoke Pharma, INC. | $31.71 | 2022-2023 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.58 | 2023 | Cyltezo |
| Qol Medical, LLC | $27.36 | 2022 | |
| Nestle Healthcare Nutrition INC. | $25.31 | 2023 | |
| Celltrion USA INC. | $24.72 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $23.29 | 2023 | Dupixent |
| Axonics, INC. | $18.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.08 | 2022 | |
| Vivus LLC | $16.67 | 2022 | |
| Boston Scientific Corporation | $14.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.